IRVINE, Calif., Aug. 24, 2006 (PRIMEZONE) -- "An advance report on what appears to be a significant stem cell breakthrough has sent one company's shares climbing northward," stated SmallCap Sentinel analyst D.R. Clark. "This is momentous news, effectively bridging a massive ethical divide that has haunted stem cells for years."
"Advanced Cell Technology, Inc. (OTCBB:ACTC) says that it has demonstrated for the first time that human embryonic stem cells can be generated without interfering with the embryo's potential for life," Clark noted. "This dramatic announcement has been posted ahead of print on the website of the journal Nature."
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California, and Worcester, Massachusetts. More information about the company is available at www.advancedcell.com.
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will address Advanced Cell Technology, Inc. (OTCBB:ACTC), StemCells Inc. (Nasdaq:STEM), Aastrom Biosciences Inc. (Nasdaq:ASTM), and Geron Corp. (Nasdaq:GERN).
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities, but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by Advanced Cell Technology, Inc. for preparation and distribution of this report and other advertising services. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding the subject companies.